What monoclonal antibody treatments are available?

As of Jan 24, 2022, sotrovimab is the only monoclonal antibody therapy recommended to be effective against the omicron variant of COVID-19.

Due to the spread of the omicron variant, the FDA has recommended the discontinuation of bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab and imdevimab) as alternative COVID-19 treatments. They were found to be ineffective against the omicron variant, and are only to be prescribed in patients suspected of having the delta variant. 

It is recommended that you contact your local public health department for more information on the distribution and availability of monoclonal antibody therapies.

All three monoclonal antibody therapies have received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA).